Great news for GenomeUp, one of the startups that graduated from our last Acceleration Program!

Just one month after the Demo Day, the startup working in the field of biomedicine collected 200k Euros from LVenture Group, some business angels of Angel Partner Group (APG) and third-party investors.

GenomeUp has developed a platform that, thanks to Artificial Intelligence, analyzes the patient's genetic makeup, identifies possible DNA mutations and compares the results with the most up-to-date scientific literature. The startup, therefore, allows hospitals, laboratories, research centers and private doctors to reduce the waiting time and costs for extremely complex diagnosis, supporting them in defining the best therapy for their patients.

"GenomeUp - claims Luigi Capello, CEO of LVenture Group - has developed a cutting-edge solution in the field of Artificial Intelligence applied to medicine, a market in constant growth that, according to recent estimates, is expected to reach 6.6 billion dollars in 2021. The results already obtained in a very short time, in collaboration with centers of excellence, demonstrate the great potential of the startup ".

According to Roberto Magnifico, President of APG: "For the success of startups, especially in the early stages, business angel support is very important, not only for financial resources but for know-how, skills, and contacts. We are very pleased with GenomeUp's growth and we are convinced that we can contribute decisively to the achievement of their objectives".

"These months have been very important for our growth - concludes Simone Gardini, CEO of GenomeUp - and the path taken together with LVenture Group and LUISS EnLabs has allowed us to involve a significant number of investors who have believed in our project. We are very pleased with the ongoing collaborations, which will allow us to continue the scientific validation of our platform and to which are added the recognition by the University of Siena of a doctoral position within our startup".

To date, GenomeUp can boast collaborations with the Bambino Gesù Pediatric Hospital and the Tor Vergata Polyclinic in Rome, where the testing phase has produced significant results, significantly reducing the costs and timing of the analyzes performed.